Ep. 210 Personalizing ADT Across the Prostate Cancer Spectrum with Dr. Rana McKay

1651.82 - 1673.806 Dr. Rana McKay

Yeah, very good question. So I think certainly in the biochemical recurrence setting, that's where I'm thinking of more intermittent ADT. And there's really no data to suggest that continuous ADT is associated with better outcomes, probably increases the risk of toxicity. And so giving them opportunities where they can have, patients can have, you know, T recovery is critically key.